Hsa_circ_0092355 Accelerates Papillary Thyroid Cancer Progression by Regulating the miR-543/PDE5A Pathway

 

 Buy Article Permissions and Reprints

Abstract

CircRNAs have been found to participate in the progression of various tumors. In the present study, we aimed to clarify the role of hsa_circ_0092355 in papillary thyroid cancer (PTC) cell development. RT-qPCR was used to determine the expression of hsa_circ_0092355, miR-543, and PDE5A. PTC cell proliferation was ascertained via a cell colony formation assay and the CCK-8 test. Western blotting was performed to examine the expression levels of PDE5A and apoptosis-associated proteins (Bcl-2 and Bax) in PTC cells. A scratch wound assay was performed to measure the migration of PTC cells. A mouse xenograft test was performed to assess the effects of hsa_circ_0092355 in vivo. RIP and dual-luciferase reporter assays confirmed the association between miR-543 and hsa_circ_0092355 or PDE5A. Associations between miR-543, hsa_circ_0092355, and PDE5A were evaluated using Pearson’s correlation coefficient. Upregulation of hsa_circ_0092355 was observed in PTC tissues. The hsa_circ_0092355 knockdown blocked the proliferation and migration of PTC cells and induced apoptosis. Moreover, hsa_circ_0092355 knockdown blocked PTC xenograft tumor growth in vivo. The miR-543 inhibitor could reverse the changes induced by hsa_circ_0092355 knockdown by hsa_circ_0092355 targeting miR-543. Furthermore, miR-543 suppresses PTC progression by downregulating PDE5A expression. Our findings suggest that the PTC tumor promoter hsa_circ_0092355 may promote carcinogenesis by controlling the miR-543/PDE5A pathway.

^* Co-Corresponding authors

Publication History

Received: 26 June 2023

Accepted after revision: 05 December 2023

Article published online:
29 January 2024

© 2024. Thieme. All rights reserved.

Georg Thieme Verlag
Rüdigerstraße 14, 70469 Stuttgart, Germany

• References

• 1 Sung H, Ferlay J, Siegel RL. et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2021; 71: 209-249
  CrossrefPubMedGoogle Scholar
• 2 Abdullah MI, Junit SM, Ng KL. et al. Papillary thyroid cancer: genetic alterations and molecular biomarker investigations. Int J Med Sci 2019; 16: 450-460
  CrossrefPubMedGoogle Scholar
• 3 Cheng Q, Li X, Acharya CR. et al. A novel integrative risk index of papillary thyroid cancer progression combining genomic alterations and clinical factors. Oncotarget 2017; 8: 16690-16703
  CrossrefPubMedGoogle Scholar
• 4 Seib CD, Sosa JA. Evolving understanding of the epidemiology of thyroid cancer. Endocrinol Metab Clin North Am 2019; 48: 23-35
  CrossrefPubMedGoogle Scholar
• 5 Chen LL. The expanding regulatory mechanisms and cellular functions of circular RNAs. Nat Rev Mol Cell Biol 2020; 21: 475-490
  CrossrefPubMedGoogle Scholar
• 6 Patop IL, Kadener S. circRNAs in cancer. Curr Opin Genet Dev 2018; 48: 121-127
  CrossrefPubMedGoogle Scholar
• 7 Yao Y, Chen X, Yang H. et al. Hsa_circ_0058124 promotes papillary thyroid cancer tumorigenesis and invasiveness through the NOTCH3/GATAD2A axis. J Exp Clin Cancer Res 2019; 38: 318
  CrossrefPubMedGoogle Scholar
• 8 Zhang W, Liu T, Li T. et al. Hsa_circRNA_102002 facilitates metastasis of papillary thyroid cancer through regulating miR-488-3p/HAS2 axis. Cancer Gene Ther 2021; 28: 279-293
  CrossrefPubMedGoogle Scholar
• 9 Huang C, Su X, Zhou DL. et al. A diagnostic and predictive lncRNA lnc-MPEG1-1 promotes the proliferation and metastasis of papillary thyroid cancer cells by occupying miR-766-5p. Mol Ther Nucleic Acids 2022; 28: 408-422
  CrossrefPubMedGoogle Scholar
• 10 Wang D, Guo C, Kong T. et al. Serum miR-22 may be a biomarker for papillary thyroid cancer. Oncol Lett 2019; 17: 3355-3361
  PubMedGoogle Scholar
• 11 Chen L, Wang X, Ji C. et al. MiR-506-3p suppresses papillary thyroid cancer cells tumorigenesis by targeting YAP1. Pathol Res Pract 2020; 216: 153231
  CrossrefPubMedGoogle Scholar
• 12 Qiu J, Zhang W, Zang C. et al. Identification of key genes and miRNAs markers of papillary thyroid cancer. Biol Res 2018; 51: 45
  CrossrefPubMedGoogle Scholar
• 13 Yu Q, Zhang Z, He B. et al. MiR-543 functions as tumor suppressor in ovarian cancer by targeting TWIST1. J Biol Regul Homeost Agents 2020; 34: 101-110
  PubMedGoogle Scholar
• 14 Liu X, Gan L, Zhang J. miR-543 inhibites cervical cancer growth and metastasis by targeting TRPM7. Chem Biol Interact 2019; 302: 83-92
  CrossrefPubMedGoogle Scholar
• 15 Yin S, Yang M, Li X. et al. Peripheral blood circulating microRNA-4636/-143 for the prognosis of cervical cancer. J Cell Biochem 2020; 121: 596-608
  CrossrefPubMedGoogle Scholar
• 16 Lou W, Ding B, Wang J. et al. The involvement of the hsa_circ_0088494-miR-876-3p-CTNNB1/CCND1 axis in carcinogenesis and progression of papillary thyroid carcinoma. Front Cell Dev Biol 2020; 8: 605940
  CrossrefPubMedGoogle Scholar
• 17 Yang Y, Ding L, Li Y. et al. Hsa_circ_0039411 promotes tumorigenesis and progression of papillary thyroid cancer by miR-1179/ABCA9 and miR-1205/MTA1 signaling pathways. J Cell Physiol 2020; 235: 1321-1329
  CrossrefPubMedGoogle Scholar
• 18 Li Z, Xu J, Guan H. et al. Circ_0059354 aggravates the progression of papillary thyroid carcinoma by elevating ARFGEF1 through sponging miR-766-3p. J Endocrinol Invest 2022; 45: 825-836
  CrossrefPubMedGoogle Scholar
• 19 Panda AC. Circular RNAs act as miRNA sponges. Adv Exp Med Biol 2018; 1087: 67-79
  CrossrefPubMedGoogle Scholar
• 20 Pan Y, Xu T, Liu Y. et al. Upregulated circular RNA circ_0025033 promotes papillary thyroid cancer cell proliferation and invasion via sponging miR-1231 and miR-1304. Biochem Biophys Res Commun 2019; 510: 334-338
  CrossrefPubMedGoogle Scholar
• 21 Qi Y, He J, Zhang Y. et al. Circular RNA hsa_circ_0001666 sponges miR‑330‑5p, miR‑193a‑5p and miR‑326, and promotes papillary thyroid carcinoma progression via upregulation of ETV4. Oncol Rep 2021; 45: 50
  CrossrefPubMedGoogle Scholar
• 22 Li R, Hou S, Zou M. et al. miR-543 impairs cell proliferation, migration, and invasion in breast cancer by suppressing VCAN. Biochem Biophys Res Commun 2021; 570: 191-198
  CrossrefPubMedGoogle Scholar
• 23 Wang D, Cai L, Tian X. et al. MiR-543 promotes tumorigenesis and angiogenesis in non-small cell lung cancer via modulating metastasis associated protein 1. Mol Med 2020; 26: 44
  CrossrefPubMedGoogle Scholar
• 24 Zhai F, Cao C, Zhang L. et al. miR-543 promotes colorectal cancer proliferation and metastasis by targeting KLF4. Oncotarget 2017; 8: 59246-59256
  CrossrefPubMedGoogle Scholar
• 25 Takimoto E, Champion HC, Belardi D. et al. cGMP catabolism by phosphodiesterase 5A regulates cardiac adrenergic stimulation by NOS3-dependent mechanism. Circ Res 2005; 96: 100-109
  CrossrefPubMedGoogle Scholar
• 26 Sponziello M, Verrienti A, Rosignolo F. et al. PDE5 expression in human thyroid tumors and effects of PDE5 inhibitors on growth and migration of cancer cells. Endocrine 2015; 50: 434-441
  CrossrefPubMedGoogle Scholar
• 27 Lee HY, Li CC, Li WM. et al. Identification of potential genes in upper tract urothelial carcinoma using next-generation sequencing with bioinformatics and in vitro analyses. PeerJ 2021; 9: e11343
  CrossrefPubMedGoogle Scholar
• 28 Arozarena I, Sanchez-Laorden B, Packer L. et al. Oncogenic BRAF induces melanoma cell invasion by downregulating the cGMP-specific phosphodiesterase PDE5A. Cancer Cell 2011; 19: 45-57
  CrossrefPubMedGoogle Scholar
• 29 Nagel S, Schneider B, Rosenwald A. et al. t(4;8)(q27;q24) in Hodgkin lymphoma cells targets phosphodiesterase PDE5A and homeobox gene ZHX2. Genes Chromosomes Cancer 2011; 50: 996-1009
  CrossrefPubMedGoogle Scholar